Clinical trial
A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in…
NCT00320255 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00320255 |
|---|---|
| Title | A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer |
| Official title | A Randomized, Double-blind, Placebo-controlled Study of Apixaban for the Prevention of Thromboembolic Events in Patients Undergoing Treatment for Advanced Cancer: A Phase 2 Pilot Study |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Ontario Clinical Oncology Group (OCOG) |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thrombosis, Cancer, Pulmonary Embolism |
| Intervention type | Drug |
| Interventions | Apixaban, Placebo |
| Enrollment | 130 |
| Start date | Jun 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | May 3, 2006 |
| Last update posted | Aug 16, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: